Medicine of erdosteine composition capsule for treating airway inflammation

Abstract

The invention discloses medicine of an erdosteine composition capsule for treating airway inflammation, and belongs to the technical field of medicine. The erdosteine composition capsule is prepared from erdosteine, starch, nordihydroguaiaretic acid, 95-percent ethanol, polyvidone K30 and talcum. The erdosteine is a novel crystal form compound; an X-ray powder diffraction pattern obtained through Cu-Ka ray measurement is shown as a Figure 1; the medicine belongs to the erdosteine different from that reported in the prior art. Experiments show that the erdosteine novel crystal form compound has better solubility and higher stability; the prepared capsule has high dissolution rate and good stability, and is very suitable for clinic application.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a capsule of erdosteine ​​composition for treating respiratory inflammation. Background technique [0002] Phlegm is the product of respiratory inflammation, which can irritate the respiratory mucosa, cause cough and asthma, and aggravate infection. When patients with acute and chronic bronchitis or chronic lung disease have respiratory failure, if the patient's sputum is too viscous or forms sputum plugs, it can block the airway and cause suffocation. Therefore, it is of great significance to use mucus sputum regulators to dissolve mucus sputum, make it thinner, lower its viscosity, accelerate the movement of mucous membranes and cilia in the respiratory tract, and improve the transport function. [0003] The currently marketed mucus regulators, such as bromhexine, sodium thioethanesulfonate, and carbocysteine, all have varying degrees of mucus regulation, but they have some pha...

AI Technical Summary

Problems solved by technology

[0005] Erdosteine ​​has poor water solubility and low effective bioavailability in the human body, and the absorption rate of the drug in the body is often determined by the speed of dissolution. The drug in the solid preparation must be disintegrated and dissolved before being absorbed. Then the process of turning into a solution, if the drug is not easily released from the formulation or the drug dissolves very slowly, there may be problems with the rate or extent of drug absorption in the formulation

[0006] Existing approaches to solve the poor water solubility of erdosteine ​​mainly include changing the dosage form, such as CN101606931B making it into dispersible tablets. Although the above preparations have improved the water solubility of the drug to a certain extent, there are also many defects.

Images